Halma plc HLMA
LondonIndustrial conglomeratesFinancials to Mar 31, 2026 · Updated Nov 11, 2026
Moat ranks
Balance sheet
| £B | Mar '25 | Mar '26 |
|---|---|---|
| Cash | 0.3 | 0.1 |
| Securities | 0.0 | 0.0 |
| Debt | 0.7 | 0.8 |
| Net cash | -0.4 | -0.7 |
| Equity | 1.9 | 2.2 |
- Debt / EBITDA
- 1.23×
- Debt / equity
- 0.37×
- Leases (3/31/26)
- £108M
- Diluted shares
- 379M
- Book value / share
- £5.72
- Price / book
- 6.1×
- Net cash / share
- −£1.74
- Market cap
- £13.2B
- Enterprise value
- £13.8B
Per-share record
Key indicators
| Indicator | Latest | Vs year ago | Last 8 halves |
|---|---|---|---|
| Revenue growth | 14.6% | +6.3 pts | |
| Operating margin | 20.0% | +0.9 pts | |
| FCF margin | 19.0% | -4.2 pts | |
| Capex / revenue | 2.7% | +0.0 pts | |
| Gross margin | – | – | – |
| Net margin | 13.8% | +0.1 pts | |
| R&D / revenue | – | – | – |
| Stock pay / revenue | – | – | – |
Margins and growth from reported quarters; company KPIs as reported in results releases.
About HLMA
Halma owns decentralized safety, environmental measurement, photonics and healthcare businesses. FY2026 revenue was GBP 2.6 billion, led by Environmental & Analysis.
- Sep 24, 2026
Halma raised FY2027 adjusted EBIT margin guidance to 23.5–24%, reflecting operational delivery and product and portfolio mix. Organic revenue growth guidance remains low double digits.
- Sep 1, 2026
Steve Brown became Environmental & Analysis Sector Chief Executive, moving from Healthcare. Marc Ronchetti remains Group Chief Executive.
- Sep 2026
Halma completed the acquisition of the three Pyxis companies for a maximum USD 200 million, extending real-time water-quality monitoring.
- Sep 2026
Bill Stoval became Healthcare Sector Chief Executive, moving from Healthcare Divisional Chief Executive and joining the Executive Board.
- Aug 2026
Halma sold NovaBone for USD 56 million net of disposal costs, exiting bone-graft products with no material disposal gain or loss expected.
Ownership
Go deeper on HLMA
- Compare stock research toolsFundamentals, valuation and screening platforms for HLMA.19 tools
- See HLMA's price chartNo price chart here yet. See price history and indicators.17 tools
- Read HLMA's earnings callsTranscripts and audio of results calls, with management's own words.15 tools
- Investing tool dealsCurrent discounts on research, charting and tracking tools.98 deals
On this page
Financial record
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | Change 2017–26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Per share (£) | ||||||||||||
| Revenue | 2.54 | 2.84 | 3.19 | 3.53 | 3.47 | 4.02 | 4.89 | 5.37 | 5.93 | 6.81 | +11.6%/yr | |
| Cash flow | 0.46 | 0.46 | 0.58 | 0.67 | 0.73 | 0.63 | 0.68 | 1.02 | 1.30 | 1.27 | +12.0%/yr | |
| Earnings | 0.34 | 0.41 | 0.45 | 0.49 | 0.54 | 0.64 | 0.62 | 0.71 | 0.78 | 0.98 | +12.4%/yr | |
| Free cash flow | 0.36 | 0.37 | 0.47 | 0.55 | 0.62 | 0.52 | 0.56 | 0.88 | 1.14 | 1.08 | +12.9%/yr | |
| Capex | 0.09 | 0.08 | 0.11 | 0.13 | 0.11 | 0.11 | 0.12 | 0.14 | 0.16 | 0.19 | +8.0%/yr | |
| Dividends | 0.13 | 0.14 | 0.15 | 0.16 | 0.17 | 0.18 | 0.19 | 0.21 | 0.22 | 0.24 | +6.7%/yr | |
| Book value | 2.06 | 2.19 | 2.59 | 3.00 | 3.07 | 3.70 | 4.22 | 4.59 | 5.01 | 5.72 | +12.0%/yr | |
| Diluted shares (M) | 379 | 379 | 379 | 379 | 380 | 379 | 379 | 379 | 379 | 379 | +0.0%/yr | |
| Totals (£B) | ||||||||||||
| Revenue | 1.0 | 1.1 | 1.2 | 1.3 | 1.3 | 1.5 | 1.9 | 2.0 | 2.2 | 2.6 | +11.6%/yr | |
| Operating income | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | 0.4 | 0.4 | 0.5 | +13.6%/yr | |
| Net income | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | 0.4 | +12.4%/yr | |
| Free cash flow | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.4 | 0.4 | +12.9%/yr | |
| Buybacks | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | +34.2%/yr | |
| Dividends | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | +6.8%/yr | |
| Net cash | -0.2 | -0.2 | -0.2 | -0.3 | -0.2 | -0.2 | -0.5 | -0.6 | -0.4 | -0.7 | −£0.5B | |
| Margins & returns (%) | ||||||||||||
| Operating margin | 17.4 | 16.8 | 18.0 | 17.4 | 18.3 | 18.3 | 16.6 | 18.1 | 18.2 | 20.4 | +3.0 pts | |
| Net margin | 13.5 | 14.3 | 14.0 | 13.8 | 15.4 | 16.0 | 12.7 | 13.2 | 13.2 | 14.4 | +0.9 pts | |
| FCF margin | 14.3 | 13.2 | 14.6 | 15.4 | 17.9 | 12.9 | 11.4 | 16.4 | 19.3 | 15.9 | +1.6 pts | |
| ROIC | 13.2 | 13.3 | 14.4 | 12.4 | 13.7 | 13.4 | 11.3 | 12.3 | 13.6 | 14.3 | +1.1 pts | |
| Return on equity | 16.7 | 18.6 | 17.3 | 16.2 | 17.4 | 17.4 | 14.7 | 15.5 | 15.6 | 17.2 | +0.5 pts | |
| R&D % of revenue | 4.1 | 4.4 | 4.3 | 4.3 | 4.2 | 4.7 | 4.7 | 4.3 | 4.2 | 4.2 | +0.0 pts | |
| Stock pay % of revenue | 0.7 | 0.8 | 0.9 | 0.9 | 1.0 | 1.0 | 1.1 | 1.1 | 1.2 | 1.2 | +0.5 pts | |
| Capex % of revenue | 3.7 | 2.9 | 3.5 | 3.6 | 3.2 | 2.6 | 2.5 | 2.5 | 2.6 | 2.7 | -0.9 pts | |
Change uses 2017 and 2026 only: compound annual growth for amounts, points for margins and returns, and the change in amount for net cash. A dash means no 2017 base. Trend shows the fiscal years.
Moat
Moat scorecard
- Strength
- –
- Confidence
- –
- Structure
- Competitive
- Durability
- –
- Trajectory
- –
- Pricing power
- moderate
- Safety36.7%Not scored: evidence insufficient
- Environmental & Analysis40.2%Not scored: evidence insufficient
- Healthcare23.2%Not scored: evidence insufficient
Moat claims
No moat claims for this company yet.
Profile change log
- Oct 7, 2026 · analyst revision
Added the US water-regulation timing risk to the Environmental & Analysis market profile: EPA proposed a PFOA/PFOS treatment-compliance extension while retaining monitoring deadlines. Testing demand and treatment capital spending can move at different times; Halma does not disclose a separate PFAS revenue line.
- Oct 7, 2026 · business change
Halma raised FY2027 adjusted EBIT margin guidance to 23.5–24%, reflecting operational delivery and product and portfolio mix. Organic revenue growth guidance remains low double digits.
- Oct 7, 2026 · business change
Bill Stoval became Healthcare Sector Chief Executive, moving from Healthcare Divisional Chief Executive and joining the Executive Board.
- Oct 7, 2026 · business change
Steve Brown became Environmental & Analysis Sector Chief Executive, moving from Healthcare. Marc Ronchetti remains Group Chief Executive.
- Oct 7, 2026 · business change
Halma completed the acquisition of the three Pyxis companies for a maximum USD 200 million, extending real-time water-quality monitoring.
- Oct 7, 2026 · business change
Halma sold NovaBone for USD 56 million net of disposal costs, exiting bone-graft products with no material disposal gain or loss expected.
- Oct 7, 2026 · business change
Halma bought Dreampath Diagnostics for a maximum EUR 279 million, adding automated pathology-sample tracking and storage.
- Oct 7, 2026 · business change
Halma bought Näslund Medical for a maximum USD 45 million, adding cancer-treatment fiducial markers to IZI Medical.
- Oct 7, 2026 · business change
Halma bought itemedical for a maximum EUR 23 million, adding hospital device-data integration to SSG.
- Oct 7, 2026 · business change
Halma sold Cardios for BRL 82 million. The expected GBP 4 million loss reflects currency devaluation since acquisition.
- Oct 7, 2026 · business change
Halma bought Surgistar for USD 90 million, expanding MST’s ophthalmic surgical instruments.
- Oct 7, 2026 · business change
Halma sold Labsphere for USD 42 million. The sale reduces optical calibration exposure; its Chinese entity closed on 16 April.
- Oct 7, 2026 · business change
Halma bought DCR Inspection Systems for GBP 8 million, adding rental and service capability to Minicam.
- Oct 7, 2026 · business change
Nuvonic licensed certain regional products to FluidSmile for GBP 9.9 million and bought a 35% associate interest for the same amount. The licence added GBP 9.3 million one-time operating profit.
- Oct 7, 2026 · business change
Halma sold Texecom for GBP 64.8 million, generating a GBP 34.0 million one-time gain and reducing security-alarm exposure.
- Oct 7, 2026 · business change
Halma sold Fiberguide for GBP 27.6 million before disposal costs, reducing fibre-optic exposure and generating a one-time disposal gain.
- Oct 7, 2026 · analyst revision
Added management, the investment debate and three market profiles. Kept market sizes and shares unreported where no source matches the full segment product mix.
- Oct 7, 2026 · analyst revision
Verified FY2026 segment revenue and retained all three insufficient-evidence assessments. Apollo panel compatibility and Avo co-development show possible product switching costs, but revenue coverage and retention are not disclosed. Removed sector operating-profit shares because sector adjusted profits omit corporate costs; corrected itemedical and Näslund acquisition months from July to June.
- Oct 7, 2026 · analyst revision
The owner changed the industry to Industrial conglomerates because Halma combines decentralized safety, environmental measurement and healthcare businesses in a diversified operating group.
Industry & peers
Peer map
Hover a point for its values; click a peer to compare. Dashed lines: industry medians.
Environmental measurement and custom photonics
Environmental and resource monitoring, water analysis and treatment instruments, specialist measurement systems and custom optical or photonic subsystems. These are distinct markets; this profile excludes commodity telecom equipment, semiconductor foundries and laboratory research services.
- Agilent
- Danaher
- Thermo Fisher Scientific
- Shimadzu
- Emerson
- Honeywell
| Stocks | Moat | Gross m. | Op. m. | |
|---|---|---|---|---|
| HLMA | – | – | 20.4% | |
| Industry median | 4 | 50 | – | – |
| Sector median | 77 | 75 | 64.7% | 23.8% |
| All stocks median | 398 | 76 | 53.1% | 20.0% |
Moat medians cover every stock. Margin medians count only stocks with collected numbers and need at least three.
Drivers & risks
- Water quality, resource scarcity and pollution rules have a strong long-run effect on monitoring needs. Utility budgets and regulatory enforcement govern when orders turn into sales.
- Data-centre investment and demand for faster data transfer have a strong effect on custom photonics programmes. Halma’s FY2026 large-customer photonics revenue rose 52%, showing that this part can move faster than environmental instruments.
- Industrial and infrastructure investment have a moderate to strong effect on gas, process and underground measurement equipment; interest rates and economic confidence can postpone projects.
- Currency translation is material for global suppliers. Electronics, specialised materials, labour and tariffs affect production costs; customer-owned designs can constrain a manufacturer’s bargaining power.
- A major photonics customer can cut spending or redesign a programme. Halma’s largest Environmental & Analysis buyer represented 20% of FY2026 group revenue.
- Technology change can make an optical design obsolete or move production to another vendor. Avo states that the customer owns the intellectual property.
- Environmental instruments face competition from broad analytical suppliers and specialist vendors; leadership in one sensing niche does not establish a groupwide market share.
- Utility funding constraints, slower industrial activity and delayed regulatory treatment deadlines can postpone projects. EPA proposed an optional extension of US PFOA/PFOS compliance to 2031 in May 2026, while keeping monitoring deadlines.
- Export controls, tariffs and specialised component shortages can raise costs or limit sales; failures in safety-critical measurements can also create liability.
Bulls & bears
Can Halma keep organic cash generation broad enough to fund acquisitions and sustain margins when its largest photonics customer slows?
Arguments
What to watch
- 1Organic revenue and adjusted profit growth by sector, with photonics and licence income identified separately.
- 2Largest customer revenue share and order intake versus revenue.
- 3Operating cash flow, capex, acquisition cash paid and debt, alongside reported return on total invested capital.
Next check: 19 November 2026 half-year results: compare cash generation and sector demand with the September margin upgrade; check Pyxis and Dreampath contribution and disposal results.
Sources: company filings and dated sources collected for Find My Moat; market cap as of Nov 10, 2026. Not investment advice.
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.